Status:
COMPLETED
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine containing regimen.
Eligibility Criteria
Inclusion
- Patients who suffer from unresectable and/or metastatic, measurable RCC histologically or cytologically documented.
- Patients with rare subtypes of RCC, such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors, are excluded from study participation.
Exclusion
- More than three regimens of previous treatment for RCC
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00661375
Start Date
November 1 2004
End Date
March 1 2006
Last Update
December 25 2014
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya, Aichi-ken, Japan, 466-8560
2
Akita, Akita, Japan, 010-8543
3
Asahi, Chiba, Japan, 289-2511
4
Chiba, Chiba, Japan, 260-0801